Entrada Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep '24 Sep 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Revenue	215.23	129.01	-	-	-	-
Cost of Revenue	120.19	99.88	66.61	-	-	-
Gross Profit	95.04	29.13	-66.61	-	-	-
Selling, General & Admin	37.26	32.29	30.64	15.2	5.57	3.61
Research & Development	-	-	-	35.93	21.1	8.22
Operating Expenses	37.26	32.29	30.64	51.13	26.67	11.82
Operating Income	57.78	-3.16	-97.25	-51.13	-26.67	-11.82
Interest & Investment Income	18.64	15.22	2.63	0.04	0.16	0.45
Other Non Operating Income (Expenses)	-	-	-	-	-	6.27
EBT Excluding Unusual Items	76.42	12.06	-94.62	-51.08	-26.5	-5.1
Gain (Loss) on Sale of Assets	-	-	-	-0.07	-0.02	-
Pretax Income	76.42	12.06	-94.62	-51.16	-26.52	-5.1
Income Tax Expense	21.47	18.74	-	-	-	-
Net Income	54.95	-6.69	-94.62	-51.16	-26.52	-5.1
Net Income to Common	54.95	-6.69	-94.62	-51.16	-26.52	-5.1
Shares Outstanding (Basic)	35	33	31	6	1	1
Shares Outstanding (Diluted)	36	33	31	6	1	1
Shares Change (YoY)	9.14%	5.61%	399.27%	467.09%	18.45%	-
EPS (Basic)	1.55	-0.20	-3.02	-8.16	-24.00	-5.47
EPS (Diluted)	1.55	-0.20	-3.02	-8.16	-24.00	-5.47
Free Cash Flow	-17.46	134.19	-96.67	-55.44	-27.89	-11.43
Free Cash Flow Per Share	-0.49	4.06	-3.09	-8.85	-25.23	-12.25
Gross Margin	44.16%	22.58%	-	-	-	-
Operating Margin	26.85%	-2.45%	-	-	-	-
Profit Margin	25.53%	-5.18%	-	-	-	-
Free Cash Flow Margin	-8.11%	104.01%	-	-	-	-
EBITDA	61.3	-0.32	-95.35	-50.01	-26.34	-11.72
EBITDA Margin	28.48%	-0.25%	-	-	-	-
D&A For EBITDA	3.52	2.84	1.9	1.12	0.33	0.1
EBIT	57.78	-3.16	-97.25	-51.13	-26.67	-11.82
EBIT Margin	26.85%	-2.45%	-	-	-	-
Effective Tax Rate	28.09%	155.45%	-	-	-	-

Source: S&P Capital IQ. Standard template. Financial Sources.